Arbitration Bid Rejected, Litigation Moves Forward
Earlier this year, in February 2025, Judge Cartwright had already denied Outliers’ attempt to compel arbitration, ruling that the company failed to prove LeDoux had agreed to such terms.
The ongoing case pits a former military medical professional against a Silicon Valley-backed supplement maker, testing the boundaries between consumer trust, product labeling, and the growing nootropics industry.
Legal Teams on Both Sides
LeDoux is represented by Jocelyn C. Stewart of the Law Office of Jocelyn C. Stewart Corp.
Outliers Inc., along with Freed and Rubin, is defended by Michelle Stratton, Richard Houghton, Dane Ball, and Christian McGuire of Murphy Ball Stratton LLP, alongside Jeremy E. Roller of Arete Law Group PLLC.
Meanwhile, associated companies Brand Nutraceuticals Inc. and Brand Packaging Group Inc. are represented by David J. Fisher, Daniel Olsen, and Joshua N. Severit of MG+M The Law Firm.
The Broader Implications
The outlier drug executives suit could have major implications for the booming cognitive supplement market, raising questions about ingredient transparency and regulatory oversight.
For now, Judge Cartwright’s order ensures that LeDoux’s claims against Outliers Inc. will proceed, keeping alive a legal battle that intertwines the promise of “smart drugs” with the peril of hidden ingredients — a modern cautionary tale for consumers chasing performance in pill form.
